TELA250117C7500
- 0.05
- 0.000.00%
TELA Bio Newsroom
Earnings Call Summary | TELA Bio(TELA.US) Q3 2024 Earnings Conference
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
The Past Five Years for TELA Bio (NASDAQ:TELA) Investors Has Not Been Profitable
TELA Bio to Participate in Piper Sandler's 36th Annual Healthcare Conference
JMP Securities Maintains TELA Bio(TELA.US) With Buy Rating, Maintains Target Price $12
Piper Sandler Maintains TELA Bio(TELA.US) With Buy Rating, Cuts Target Price to $5
Market Might Still Lack Some Conviction On TELA Bio, Inc. (NASDAQ:TELA) Even After 27% Share Price Boost
TELA Bio | 10-Q: Q3 2024 Earnings Report
Q3 2024 TELA Bio Inc Earnings Call
CCORF Maintains TELA Bio(TELA.US) With Buy Rating, Maintains Target Price $12
Piper Sandler Maintains Overweight on TELA Bio, Lowers Price Target to $5
TELA Bio Analyst Ratings
TELA Bio's Strategic Recovery and Growth Potential: A Buy Rating With a $12 Target
TELA Bio, Inc. (TELA) Reports Q3 Loss, Lags Revenue Estimates
TELA Bio Achieves Record Q3 Revenue Growth in 2024
TELA Bio | 8-K: TELA Bio Reports Third Quarter 2024 Financial Results
Express News | TELA Bio Outlook FY Revenue USD 74.5-76.5 Million
Express News | TELA Bio Q3 Income From Operations USD -9.365 Million
Express News | TELA Bio Q3 Basic EPS USD -0.42